Search Results 381-390 of 17887 for Coagulation

1. A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) - Mayo Clinic

   Eligible study subjects must exhibit acceptable liver, renal, and coagulation function as assessed by laboratory tests. Females and males must practice true ...

2. Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) - Mayo Clinic

   ... coagulation disorders, * History of gastrointestinal bleeding * Major surgery within 8 weeks prior to screening * History of hypersensitivity to any of the ...

3. Cardiogenic shock - Symptoms & causes - Mayo Clinic

   Most often the result of a large or severe heart attack, this rare condition can be deadly if not treated right away.

4. A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression - Mayo Clinic

   Adequate coagulation parameters (within 21 days prior to registration), International Normalized Ratio (INR) ≤1.5; Activated ProThrombin Time (APTT) ≤ 1.5 x ...

5. Sym021 in Combination with Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients with Advanced Biliary Tract Carcinomas - Mayo Clinic

   Coagulation. International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN unless the patient is ...

6. A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ Capsules in Patients With Advanced Solid Tumors - Mayo Clinic

   Acceptable coagulation status: PT ≤ 1.5 times institutional ULN;; PTT ≤ 1.5 times institutional ULN. For men and women of child-producing potential, the ...

7. Omega-3 Fatty Acids to Combat Sarcopenia - Mayo Clinic

   Anti-coagulant therapy (warfarin/heparin); INR >3; Use of systemic glucocorticoids; Chronic use of NSAIDS or aspirin; Pregnancy or breastfeeding; Alcohol ...

8. A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors - Mayo Clinic

   Coagulation: Prothrombin time (PT)/international normalized ratio (INR) < 1.5 x the upper limit of normal (ULN) and activated partial thromboplastin time ...

9. A Study Of SPX-303, A Bispecific Antibody Targeting LILRB2 And PD-L1 In Patients With Solid Tumors - Mayo Clinic

   Adequate coagulation function: INR, PT and aPPT ≤ 1.5x ULN except for patients on anti-coagulation as long as PT, aPPT, or INR are within intended range.

10. GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC - Mayo Clinic

    anti-coagulation, it must be clinically acceptable to hold anti-coagulation for the injection procedures per investigator discretion 12. Serum creatinine ...